▎WuXiEdited by Kant Content Team

Today, the well-known business media "Fast Company" announced "List of the 10 Most Innovative Pharmaceutical Companies Globally”。This list reflects significant breakthroughs in treating stubborn diseases over the past year, with many companies on the list bringing "first-ever" or "game-changing" therapies for previously difficult-to-treat conditions.These fields include Alzheimer's disease, hemophilia, depression, etc. These selected companies represent the vanguard of humanity's journey in pharmaceutical innovation, and their innovative technologies also represent potential directions for the future of the industry.

Image Source: 123RF

Novo Nordisk: Unlocking the Potential of GLP-1 Therapy Beyond Diabetes and Weight Loss

Novo Nordisk's重磅药物司美格鲁肽（semaglutide）分别在2017年与2021年获美国FDA批准上市，用于Type 2 DiabetesPatient's Blood Glucose Control (Brand Name: Ozempic) and TreatmentCommon ObesityPatient (Brand Name: Wegovy), the successful launch of this drug has driven the overall growth of the company. HoweverNovo Nordisk does not stop there. In addition to continuously expanding its presence in the fields of weight loss and diabetes, the company is also actively exploring the potential applications of semaglutide in various diseases., including treatments for early Alzheimer's disease, non-cirrhotic nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), and reducing the risk of occurrence in patients with type 2 diabetes and chronic kidney disease (CKD).Risk of Renal Disease-Related Events, etc. This month,Wegovy Again Approved in the U.S.FDA Approval, becoming the first weight-loss drug approved to help prevent major cardiovascular events in adults with cardiovascular disease and obesity or overweight.

Reference Reading:Weight Loss Exceeds 13% in 12 Weeks! Latest Results and Development Strategy of Novo Nordisk's Next-Generation Weight Loss Therapy Revealed

Vertex Pharmaceuticals: Advancing the First CRISPR Therapy to Market

In November 2023, Casgevy (exagamglogene autotemcel, exa-cel), a CRISPR gene-editing therapy co-developed by Vertex and its partner CRISPR Therapeutics, was approved for marketing in the UK.BecomeThe World's First ApprovedCRISPR Gene Editing Therapy.The U.S. FDA subsequently approved the therapy for treatment in December 2023 and January of this year.Sickle Cell Anemia(SCD) and Transfusion Dependencyβ-Thalassemia(TDT) patients.

In addition to focusing on the development of gene-editing therapies, Vertex is also about to submit its selective NaV1.8 inhibitor VX-548 for the treatment of moderate to severe acute pain.New Drug Application。The press release noted that, if approved, this would become the first new painkiller with a novel mechanism of action in decades.In addition, Vertex also announced last month that its next-generation triple combination therapy (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) achieved positive results in three Phase 3 clinical trials.Positive ResultsThe company is expected to file for marketing authorization with regulatory authorities in the U.S., EU, and Canada by mid-2024.

Eisai: Committed to Developing Alzheimer's Disease Therapies Targeting Amyloid Plaques

January last year,ByJointly developed by Eisai and BiogenLeqembi(Lecanemab) receives accelerated approval from the U.S. FDA for the treatment of Alzheimer's disease.BecomeThe first approved therapy capable of slowing disease progression and alleviating cognitive decline.Leqembi and further received FDA approval in July of the same yearFull Approval, this isFDA Fully Approves an Alzheimer's Drug for the First Time in 20 Years.This drug also made it toTime Magazine's 2023 AnnualBest InventionThe list.

Leqembi specifically binds to soluble oligomers of β-amyloid. It not only neutralizes and clears toxic soluble oligomers but also rapidly reduces amyloid plaque deposition in the patient's brain.In the Phase 3 clinical trial named CLARITY AD, Leqembi significantly reduced the rate of increase in the primary endpoint CDR-SB compared to placebo (a higher CDR-SB score indicates lower clinical function in patients). At week 79, the average change in CDR-SB score decreased by 27% compared to the placebo group. The company is also developing a more convenientLeqembiSubcutaneous Formulation, RelatedThe Biologics License Application (BLA) is expected to be submitted to the FDA in the near future.

SAGE Therapeutics: Develops Faster and Simpler Treatment for Postpartum Depression

The U.S. FDA in August last yearApprovalDeveloped jointly by Sage Therapeutics and BiogenZurzuvae (zuranolone) has been launched, making it the first approved oral therapy for the treatment of postpartum depression (PPD) in adult patients.Previously, treatment for PPD patients was only available through intravenous injection administered by healthcare professionals in medical institutions.PPD is one of the most common complications during and after pregnancy. PPD may have serious negative effects on women, including severe dysfunction, low mood, and/or loss of interest in the newborn, along with associated depressive symptoms. Previously publishedPhase 3 trial results show that Zurzuvae met the primary endpoint as well as all key secondary endpoints.Participants experienced rapid and significant improvement in depressive symptoms starting on the 3rd day of medication use, which continued until the 45th day.

Perrigo: Launches First Over-the-Counter Contraceptive Pill

Perrigo's Opill (norgestrel) tablets received approval in July 2023.Approved by the U.S. FDA, becoming the first daily oral contraceptive available without a prescription.Opill contains only one active ingredient, progestin.Users can purchase them independently at general pharmacies, convenience stores, and online. In the past,Formulations and dosages of other approved oral contraceptives can only be obtained with a prescription from healthcare professionals. According to an FDA press release, there are approximately 6.1 million pregnancies in the United States each year, nearly half of which are unintended. Unintended pregnancies are closely associated with adverse pregnancy outcomes, including reduced access to early prenatal care, increased risk of preterm birth, and negative consequences for newborns, as well as child development and health.Using over-the-counter Opil may help reduce the incidence of unintended pregnancies and their potential negative consequences.

Sanofi: Protecting Unique Vulnerable Patient Populations

In 2023, two innovative therapies from Sanofi received approval from the U.S. FDA, addressing unmet medical needs for distinct vulnerable patient populations.February 2023,Sanofi's Altuviiio Receives FDA Approval in the U.S. as the First Therapy to Prevent Bleeding in Hemophilia A Patients with Just Once-Weekly TreatmentPatients with Hemophilia A typically require 3-4 infusions of Factor VIII per week, which brings significant inconvenience to their lives. In the clinical trial named XTEND-1, Altuviiio demonstrated superiority over prophylactic Factor VIII treatment in preventing bleeding, significantly reducing the annual bleeding rate in patients with Hemophilia A.

In addition, Beyfortus (nirsevimab), the respiratory syncytial virus (RSV) antibody jointly developed by Sanofi and AstraZeneca, was approved for marketing by the U.S. FDA in July 2023.Beyfortus is the first therapy that requires only a single dose to provide protection against RSV for all infants and young children at risk of infection.

Astellas: Developing the First Innovative Therapy for Treating Hot Flashes

Veozah (fezolinetant), an oral medication developed by Astellas, received its first approval from the U.S. FDA in May 2023 for the treatment of moderate to severe vasomotor symptoms (VMS, commonly known as hot flashes) caused by menopause.Veozah is a neurokinin 3 (NK3) receptor antagonist that works by binding to the receptor to block its action. The neurokinin 3 receptor is involved in the brain's mechanism for regulating body temperature. Veozah is not a hormone but rather targets the neural activity responsible for menopausal hot flashes.

Phase 3b announced in July 2023Clinical Trial ResultsDisplay,From baseline to Week 24, the frequency of moderate to severe VMS was statistically significantly reduced in patients receiving 45 mg Veozah compared to the placebo group.

Blueprint Medicines: First Precision Therapy for Rare Blood Disorders

In May 2023, Blueprint Medicines CorporationAyvakit (avapritinib) ObtainedFDA Approval in the United States, for the treatment of adult patients with indolent systemic mastocytosis (SM). It is the first precision therapy approved for the treatment of indolent SM.

Ayvakit is a type 1 inhibitor that targets the kinase activation conformation and is capable of inhibiting various mutations.KITAndPDGFRAProtein kinase with gene mutations. The KIT protein D816V mutation is present in approximately 95% of SM patients.

The approval of Ayvakit was based on data from the double-blind, placebo-controlled clinical trial PIONEER. In this trial, patients with indolent SM received once-daily treatment with 25 mg of Ayvakit along with supportive care, while the control group received placebo treatment plus supportive care. Compared to placebo treatment, Ayvakit demonstrated significant improvements in the primary and all key secondary endpoints, including overall symptoms and mast cell burden.

Amgen: Expanding Access to Treatments for Autoimmune Diseases

In October 2023, Wezlana, developed by Amgen, received approval from the U.S. FDA, becoming the first of its kind.ReplaceableHeavyweight Drug Stelara's ReplaceableInterchangeable BiosimilarThis drug can treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Wezlana can be used to replace Stelara without consulting a doctor, and its launch is expected to expand the accessibility of treatments for various autoimmune diseases.

BeOne Medicines: Providing a New Option for Treating Common Leukemia

In 2023, BeOne Medicines developed a Bruton's tyrosine kinase inhibitorBrukinsa (Zanubrutinib) Approved in the United StatesFDA Approval, used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), one of the most common types of leukemia. This month, the drug received another FDAAccelerated Approval, used forTreatmentAdult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have previously received at least two lines of systemic therapy。

The results of the Phase 3 clinical trial ALPINE, published in The New England Journal of Medicine in December 2022, showed thatZanubrutinib met the criteria for superiority over the active control group in terms of progression-free survival (PFS) and overall response rate (ORR).At 24 months, the investigator-assessed progression-free survival (PFS) rate was 78.4% in the zanubrutinib group and 65.9% in the active control group. The PFS benefit was observed across all major subgroups by the Independent Review Committee (IRC), including the high-risk subgroup of patients with specific TP53 mutations.

Zanubrutinib is a BTK small molecule inhibitor independently developed by scientists at BeOne Medicines. It is currently undergoing extensive clinical trials worldwide as a monotherapy and in combination with other therapies for the treatment of various B-cell malignancies. Since new BTK is continuously synthesized in the human body, zanubrutinib is designed to achieve complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With its differentiated pharmacokinetics compared to other approved BTK inhibitors, zanubrutinib can inhibit the proliferation of malignant B cells in multiple disease-related tissues.It was first approved by the U.S. FDA in 2019, and to date, it has received FDA approval for five indications.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.